Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | PHGDH | O43175 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.40 |
| ▸ | HTR3B | O95264 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.40 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28340528 | 0.98 | LMNA (0.43) | LMNAL3MBTL1PLAUALDH1A1SIGMAR1 | |
| SCHEMBL14868762 | 0.81 | HTR3E (0.41) | LMNAALDH1A1HTR3EHTR3BHTR3A | |
| SCHEMBL28899686 | 0.81 | KMT2A (0.36) | LMNAL3MBTL1PLAUALDH1A1SIGMAR1 | |
| SCHEMBL3058170 | 0.80 | ALDH1A1 (0.48) | L3MBTL1ALDH1A1SIGMAR1KMT2AMEN1 | |
| SCHEMBL7421824 | 0.80 | LMNA (0.47) | LMNAL3MBTL1PLAUALDH1A1SIGMAR1 | |
| SCHEMBL28899703 | 0.78 | ALDH1A1 (0.38) | PLAUALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL11836946 | 0.78 | LMNA (0.48) | LMNAL3MBTL1PLAUALDH1A1SIGMAR1 | |
| SCHEMBL1743264 | 0.77 | HTR3E (0.60) | LMNAL3MBTL1PLAUALDH1A1SIGMAR1 | |
| SCHEMBL28899661 | 0.77 | ALDH1A1 (0.36) | L3MBTL1PLAUALDH1A1KMT2AMEN1 | |
| SCHEMBL725723 | 0.77 | ALDH1A1 (0.36) | PLAUALDH1A1HTR3EHTR3BHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110615886-A | Biguanide derivative antibacterial epoxy resin curing agent and preparation method thereof | 哈尔滨工程大学 | 2019-12-27 | — | — | CN | claimed |
| EP-4180482-B1 | MOISTURE-CURABLE COMPOSITION | NITTO KASEI CO LTD (JP) | 2025-12-03 | — | — | EP | disclosed |
| US-12479869-B2 | Curing catalyst used for curing of polymer, method for producing same, moisture-curable composition, and method for producing cured product | NITTO KASEI CO., LTD. (JP) | 2025-11-25 | — | — | US | disclosed |
| EP-4174053-B1 | CURING CATALYST USED FOR CURING OF POLYMER, METHOD FOR PRODUCING SAME, MOISTURE-CURABLE COMPOSITION, AND METHOD FOR PRODUCING CURED PRODUCT | NITTO KASEI CO LTD (JP) | 2025-11-19 | — | — | EP | disclosed |
| EP-4569023-A1 | COMBINATION OF CATALYTIC COMPONENTS | PolyU GmbH (DE) | 2025-06-18 | — | — | EP | disclosed |
| CN-115516041-B | Curing catalyst for curing polymer, method for producing same, moisture-curable composition, and method for producing cured product | 日东化成株式会社 | 2024-06-28 | — | — | CN | disclosed |
| WO-2024033348-A1 | COMBINATION OF CATALYTIC COMPONENTS | POLYU GMBH (DE) | 2024-02-15 | — | — | WO | disclosed |
| EP-4321573-A1 | COMBINATION OF CATALYTIC COMPONENTS | PolyU GmbH (DE) | 2024-02-14 | — | — | EP | disclosed |
| US-20240002725-A1 | COMPOSITION AND METHOD FOR TREATING SUBSTRATE | FUJIFILM CORPORATION (JP) | 2024-01-04 | — | — | US | disclosed |
| CN-117062940-A | Composition and method for treating substrate | 富士胶片株式会社 | 2023-11-14 | — | — | CN | disclosed |
| CN-102165016-B | Curable composition and cured product thereof | KANEKA CORP | 2014-03-12 | — | — | CN | disclosed |
| EP-2338938-B1 | CURABLE COMPOSITION AND CURED PRODUCT THEREOF | KANEKA CORP (JP) | 2013-07-31 | — | — | EP | disclosed |
| WO-2013103384-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ELCELYX THERAPEUTICS, INC. (US) | 2013-07-11 | — | — | WO | disclosed |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| EP-2388297-A1 | CURABLE COMPOSITION AND CURED OBJECT FORMED THEREFROM | Kaneka Corporation (JP) | 2011-11-23 | — | — | EP | disclosed |
| US-20110237723-A1 | CURABLE COMPOSITION AND CURED PRODUCT THEREOF | KANEKA CORPORATION (JP) | 2011-09-29 | — | — | US | disclosed |
| CN-102165016-A | Curable composition and cured product thereof | KANEKA CORP | 2011-08-24 | — | — | CN | disclosed |
| EP-2338938-A1 | CURABLE COMPOSITION AND CURED PRODUCT THEREOF | Kaneka Corporation (JP) | 2011-06-29 | — | — | EP | disclosed |
| EP-2267083-A1 | CURABLE COMPOSITION AND CURED MATERIAL | Kaneka Corporation (JP) | 2010-12-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479869-B2 | Curing catalyst used for curing of polymer, method for producing same, moisture-curable composition, and method for producing cured product | KDM2B, SETDB1, ASH2L | LMNA 3540/4885L3MBTL1 3304/4885PLAU 2771/4885 |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GPR119 | LMNA 2222/4885L3MBTL1 4566/4885PLAU 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.